首页> 外文OA文献 >Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks

【2h】

Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks

机译：TZT-1027的I阶段研究，一种新型合成的少剂素10衍生物和小管蛋白聚合抑制剂，每周给晚期固体瘤患者3周

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Nobuyuki Yamamoto; Masahiro Andoh; Masaaki Kawahara; Masahiro Fukuoka; Hisanobu Niitani;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks [J] . Nobuyuki Yamamoto, Masahiro Andoh, Masaaki Kawahara Cancer science. . 2009,第2期

机译：TZT-1027是一种新型合成的dolastatin 10衍生物和微管蛋白聚合抑制剂的I期研究，每周向晚期实体瘤患者提供3周
2. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses [J] . Kenji Tamura, Kazuhiko Nakagawa, Takayasu Kurata, Cancer Chemotherapy and Pharmacology . 2007,第2期

机译：TZT-1027（一种新型合成的dolastatin 10衍生物和微管蛋白聚合抑制剂）的I期研究在3周的课程中的第1天和第8天施用于患有晚期实体瘤的患者
3. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. [J] . Schoffski P, Thate B, Beutel G, Annals of oncology: official journal of the European Society for Medical Oncology . 2004,第4期

机译：TZT-1027（一种新型合成的dolastatin 10衍生物）的I期和药代动力学研究，每3周一次向晚期难治性癌症患者静脉输注1小时。
4. Phase I Clinical Trial with Her-2 B-Cell Chimeric and MultiEpitope Based Peptide Vaccines in Patients with Metastatic and/or Recurrent Solid Tumors [C] . Pravin T.P. Kaumaya, Kevin Chu Foy, Joan Garrett American Peptide Symposium . 2009

机译：患者临床试验与患有转移和/或复发性固体瘤的患者的HER-2 B细胞嵌合和多型肽疫苗
5. Structure-activity relationships and thermodynamics of combretastatin A-4 and A-1 derivatives as potential inhibitors of tubulin polymerization. [D] . Mugabe, Benon E. 2006

机译：康布雷他汀A-4和A-1衍生物作为微管蛋白聚合的潜在抑制剂的结构活性关系和热力学。
6. A Phase I Clinical Pharmacokinetic and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors [O] . Alberto J. Montero, Deukwoo Kwon, Aurea Flores, -1

机译：晚期实体瘤患者每周或每三周伊沙贝比隆和每日舒尼替尼的I期临床药代动力学和药效学研究

Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks

著录项

相似文献

相关主题

期刊订阅